Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.29 | N/A | -1.53% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.29 | N/A | -1.53% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding future expectations. They highlighted ongoing projects but did not provide specific guidance.
Management did not provide specific guidance for future performance.
The company is focusing on its core projects despite the current challenges.
This earnings report indicates that Krystal Biotech faced challenges in meeting earnings expectations, resulting in a significant stock drop of 14.04%. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. Management's defensive tone suggests they are aware of the hurdles ahead but are focusing on their ongoing projects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ECHOSTAR CORP Class A
Aug 1, 2025